Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.
Shingles, a reactivation of the herpes zoster (chickenpox) virus affects nearly 1 in 3 Americans. About 1 million cases are diagnosed each year, with some patients suffering excruciating pain and itching due to post-herpetic neuralgia (PHN), a complication of the viral infection that can last for years despite treatment.
Older adults who get the shingles vaccine have a nearly 50 percent reduced risk of developing the often debilitating disease, finds a new evidence review from The Cochrane Library.
The herpes zoster virus, which causes shingles, is becoming more common as the population ages. In Australia the number of cases has doubled between 2000 and 2010. Hospital emergency departments report a 2–6% increase in cases per year.
Writing in the latest edition of Australian Prescriber, Associate Professor Jane Hanrahan from the Faculty of Pharmacy, University of Sydney writes that UVB is the cause of sunburn, but UVA can be more damaging to the skin. It is therefore best to use broad spectrum sunscreens that block both wavebands.
Herpes zoster infection, or shingles, is not associated with cancer, show results from a study published in the Canadian Journal of Medicine
Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the treatment of chronic neuropathic pain indications.
Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.
Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.
Incyte Corporation today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Pfizer Inc. announced today top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).
Depomed, Inc. today announced that a report of Phase 3 data published online this month, ahead of the print edition, in the Clinical Journal of Pain showed that once-daily Gralise (gabapentin) tablets (1,800 mg) formulation significantly reduces intensity of pain in patients with postherpetic neuralgia (PHN).
Administration of the live attenuated herpes zoster vaccine is not associated with an increased risk for shingles shortly after vaccination in patients receiving biologic treatments for immune-mediated diseases, researchers report in JAMA.
Although some have suggested that patients receiving medication for immune-mediated diseases such as rheumatoid arthritis or psoriasis may be at increased risk of herpes zoster (HZ; shingles) shortly after receipt of the vaccine, an analysis that included nearly 20,000 vaccinated Medicare beneficiaries finds that the live zoster vaccine is not associated with an increased risk of HZ shortly after vaccination in patients currently treated with biologics, and that it is associated with a significantly reduced longer-term risk of HZ in patients with an immune-mediated disease, according to a study in the July 4 issue of JAMA.
New research from the University of Alabama at Birmingham casts doubt on the long-standing belief that the vaccine for shingles should not be given to patients taking biologics for auto-immune diseases such as rheumatoid arthritis.
Patients with inflammatory rheumatic diseases who are treated with anti-tumor necrosis factor medications are significantly more likely to experience herpes zoster infections than those treated with traditional disease-modifying anti-rheumatic drugs, study results show.
Patients with inflammatory rheumatic disease treated with one of the most effective medicines for their disease face a substantially increased risk for developing shingles, warn European researchers who suggest vaccination may be an option.
Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.
GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.